Eli Lilly's latest obesity readout is more than a win for one program. By showing that an amylin agonist added to tirzepatide can push weight loss well past what tirzepatide achieves alone, the company has given drug developers a clearer picture of where the field is heading and what it will take to compete there.
In the 48-week Phase 2b trial of 367 adults with obesity or overweight and type 2 diabetes, the top dose of EloraTZP, which pairs the selective amylin receptor agonist eloralintide with tirzepatide, cut body weight by 23.3 percent. Tirzepatide 15 mg alone delivered 14.8 percent, and eloralintide alone up to 12.3 percent. A1C fell 2.9 percentage points on the combination versus 2.4 on tirzepatide.
Lower-dose pairings also beat full-dose tirzepatide: eloralintide 6 mg with 5 mg of tirzepatide produced 19.4 percent weight loss, hinting that combinations could trade peak dosing of one drug for another.
Amylin moves from add-on to backbone
The result strengthens the case that amylin, a satiety hormone released after meals, is the most productive pathway to pair with incretins. Weight loss drugs usually underperform in people with type 2 diabetes: Novo Nordisk's CagriSema, which combines the amylin analog cagrilintide with semaglutide, produced 15.7 perc weight lossent over 68 weeks in a similar population. Cross-trial comparisons are unreliable, but the gap will not go unnoticed.
Competitors are already positioned. Novo has filed CagriSema with the FDA. Zealand Pharma and Roche published Phase 2 data for their amylin analog petrelintide last week and have started Phase 3. AbbVie reported Phase 1 results for ABBV-295, a long-acting amylin analog that produced 7.9 percent weight loss in about 12 weeks with monthly dosing.
For smaller developers, the message is that a GLP-1 agonist alone is no longer a differentiated asset. Partners and investors will increasingly ask what a candidate can be combined with.
Tolerability is the next battleground
The safety data complicate the picture. Gastrointestinal side effects were the most common adverse events and occurred more often with the combination than with either drug alone. Between 10.8 percent and 27.0 percent of participants on EloraTZP stopped treatment because of adverse events, compared with 2.9 percent on tirzepatide and 0 percent to 10.8 percent on eloralintide.
That matters because amylin's pitch has been gentler side effects. Petrelintide delivered up to 10.7 percent weight loss at 42 weeks with gastrointestinal tolerability its developers describe as placebo-like. Lilly's data suggest that advantage may shrink when amylin is layered on a potent incretin, leaving developers to choose between a milder monotherapy and a more powerful but harder-to-tolerate combination.
Lilly's headline figures also assume every participant stayed on treatment, an approach that flatters arms with high dropout. Developers benchmarking against 23.3 percent should expect regulators and payers to ask what patients achieve in practice.
What comes next
Lilly plans to start Phase 3 trials of a co-formulated EloraTZP by the end of 2026 with what it calls an "optimized escalation schedule." Both details carry lessons. Titration design is now a competitive variable, and combining two peptides in one injection adds formulation and manufacturing work that the separate injections used in Phase 2 did not test.
For the rest of the industry, that frontier leaves openings in three places: better tolerability, less frequent dosing, and oral delivery. Matching Lilly on raw weight loss looks like the hardest path of all.
